Not Yet RecruitingPhase 1

Behavioral Pharmacology of THC and Beta-Myrcene

United States32 participantsStarted 2026-07

Plain-language summary

This study will evaluate the pharmacokinetics and pharmacodynamics of vaporized b-myrcene and THC administered via inhalation.

Age range18 Years – 55 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Have provided written informed consent
✓. Be between the ages of 18 and 55
✓. Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests
✓. Test negative for drugs of abuse other than cannabis, including breath alcohol at the screening visit and at clinic admission
✓. Not be pregnant or nursing (if female). All females must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at clinic admission.
✓. Have a body mass index (BMI) in the range of 18 to 36 kg/m2
✓. Blood pressure at Screening Visit does not exceed a systolic blood pressure (SBP) of 150 mmHg or a diastolic blood pressure (DBP) of 90 mmHg
✓. Have no allergies to any of the ingredients used to prepare vapor (delta 9-THC, myrcene).

✕. Non-medical use of psychoactive drugs other than, nicotine, alcohol, or caffeine 3 month prior to the Screening Visit;
✕. History of or current evidence of significant medical (e.g. seizure disorder) or psychiatric illness (e.g. psychosis) judged by the investigator to put the participant at greater risk of experiencing an adverse event due to exposure or completion of other study procedures.
✕. Use of an OTC, systemic or topical drug(s), herbal supplement(s), or vitamin(s) within 14 days of experimental sessions; which, in the opinion of the investigator or sponsor, will interfere with the study result or the safety of the subject.
✕. Use of a prescription medication (with the exception of birth control prescriptions) within 5 half-lives for that specific drug; which, in the opinion of the investigator or sponsor, will interfere with the study result or the safety of the subject.
✕. Cannabis use that is inconsistent with protocol requirements.
✕. Clinically significant cardiac arrhythmias or vasospastic disease (e.g., Prinzmetal's angina).
✕. Individuals with anemia or who have donated blood in the prior 30 days

Self-reported Drug Effect as assessed by the Drug Effect Questionnaire (DEQ)

Timeframe: 6 hours

NCT IDNCT05432284

SponsorJohns Hopkins University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-11

Ryan Vandrey, PhD

Who can participate

Age range18 Years – 55 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Have provided written informed consent
✓. Be between the ages of 18 and 55
✓. Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests
✓. Test negative for drugs of abuse other than cannabis, including breath alcohol at the screening visit and at clinic admission
✓. Not be pregnant or nursing (if female). All females must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at clinic admission.
✓. Have a body mass index (BMI) in the range of 18 to 36 kg/m2
✓. Blood pressure at Screening Visit does not exceed a systolic blood pressure (SBP) of 150 mmHg or a diastolic blood pressure (DBP) of 90 mmHg
✓. Have no allergies to any of the ingredients used to prepare vapor (delta 9-THC, myrcene).

✕. Non-medical use of psychoactive drugs other than, nicotine, alcohol, or caffeine 3 month prior to the Screening Visit;
✕. History of or current evidence of significant medical (e.g. seizure disorder) or psychiatric illness (e.g. psychosis) judged by the investigator to put the participant at greater risk of experiencing an adverse event due to exposure or completion of other study procedures.
✕. Use of an OTC, systemic or topical drug(s), herbal supplement(s), or vitamin(s) within 14 days of experimental sessions; which, in the opinion of the investigator or sponsor, will interfere with the study result or the safety of the subject.
✕. Use of a prescription medication (with the exception of birth control prescriptions) within 5 half-lives for that specific drug; which, in the opinion of the investigator or sponsor, will interfere with the study result or the safety of the subject.
✕. Cannabis use that is inconsistent with protocol requirements.
✕. Clinically significant cardiac arrhythmias or vasospastic disease (e.g., Prinzmetal's angina).
✕. Individuals with anemia or who have donated blood in the prior 30 days